Thelansis

 Idiopathic Pulmonary Fibrosis (IPF) is a chronic condition characterized by lung scar tissue, developing gradually over several years and without any known cause. The primary symptoms associated with IPF are exercise-induced shortness of breath and a persistent, dry cough. IPF falls under interstitial lung disease (ILD), more accurately referred to as diffuse parenchymal lung disease (DPLD). Within this broad classification of lung disorders, IPF belongs explicitly to a subgroup known as idiopathic interstitial pneumonia (IIP). The typical age of presentation for IPF is around 66 years. Initial symptoms often include exertional breathlessness and persistent dry cough. When examining the lungs of IPF patients, healthcare providers frequently detect early inspiratory crackling sounds, mainly in the lower posterior lung regions. Approximately 50% of IPF patients may also exhibit clubbing of the fingers. Over time, exertional dyspnea worsens progressively, spanning months to years. IP...

  Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that affects middle-aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening or persistent and progressive scarring (fibrosis), which increases irreversibly over time. Scarring damages the air sacs, reducing the amount of oxygen in the blood. With less oxygen in the blood, everyday activities like walking can cause breathlessness. This group of lung disorders is known as ‘Diffuse Parenchymal Lung Diseases’, characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs). The progression rate may vary depending on the individual in IPF, characterized by progressive worsening of dyspnea and lung function associated with poor prognosis. IPF comprises a group of lung diseases that damage the lung by unproven causes. However, genetic susceptibility has been found to account for 35 to 40% of cases. Considering no cura...